Project Grant F31CA318262
Award Date 2/14/27
Completion Date 8/16/28
Dollars Obligated $100K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Hanover, NH 03755, USA
Similar Awards
- The National Cancer Institute awarded The Johns Hopkins University $692,609 on August 3, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate quantitative MRI applications for monitoring tumor oxygenation during radiation therapy. The project will evaluate OxytrackIMT, an elastomer-and-silicone-oil-based molecular sensor developed by Stratagen Bio Inc. (an MIT spin-off), and oxygen-enhanced MRI for longitudinal measurement of tumor partial...
- Federal Project Grant Award Summary Award Details: The National Cancer Institute (NCI) awarded O2M Technologies LLC a $1,164,814 Project Grant on September 19, 2025, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) for research extending through August 31, 2027. The award supports the development of advanced imaging methods in pulse electron paramagnetic resonance (EPR) to enable precise partial oxygen pressure (pO2) measurements for cancer diagnosis and treatment...
- The National Cancer Institute awarded Dartmouth-Hitchcock Clinic $633,819 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate advanced imaging techniques for laser interstitial thermal therapy (LITT) in the treatment of spinal metastases. The project addresses two critical technical barriers limiting clinical adoption of LITT for spinal tumors: inaccuracies in MRI thermometry caused by motion artifacts from respiration and cardiac...
- The National Cancer Institute awarded the Regents of the University of California, San Francisco $421,685 on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop hyperpolarized 13C MRI as a biomarker for predicting immunotherapy response in cancer patients. The project addresses a clinical gap in immunotherapy monitoring: current imaging methods based on computed tomography and magnetic resonance imaging cannot reliably distinguish...
- The National Institutes of Health National Cancer Institute awarded Cold Spring Harbor Laboratory $793,679 on August 6, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop whole-body redox maps for metastatic cancer therapy. The project uses protein degradation-based sensing to visualize oxidative stress in vivo across animal models of prostate cancer. The work generates two complementary, immune-competent mouse models—OXIGEM and ROXYCAP—that reveal cellular redox states...
- The National Institutes of Health Office of the Director awarded $956,000 to Advanced Center For Electron Spin Resonance Research And Technology, Inc. on September 1, 2026, under the Research Infrastructure Programs (CFDA 93.351) to purchase and install a pulsed electron spin resonance oxygen imaging system (ESROI) at Cornell University's Cornell Magnetic Resonance Imaging Facility (CMRIF). The ESROI system is the only commercially available ESR-based oxygen imager and will be the first...
- The National Institute of Biomedical Imaging and Bioengineering (part of the Department of Health and Human Services National Institutes of Health) awarded $1.314 million to Massachusetts General Hospital on June 2, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop quantitative point-of-care MRI for breast cancer screening. The research addresses the limitations of current breast cancer screening modalities by...
- The National Cancer Institute awarded the University of California, Berkeley $712,375 on April 1, 2026, through the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop the ADAPT PRO system, a single, digitally programmable radiofrequency system that enables magnetic resonance imaging of any nucleus independent of or simultaneously with others. The project runs through March 31, 2031, with work performed in Berkeley, California. The ADAPT PRO system addresses a technical...
- The National Cancer Institute awarded Trustees of Dartmouth College $509,906 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate information preferences, risk perceptions, and tradeoffs in multi-cancer early detection (MCED) decisions through a randomized vignette trial. The research addresses the clinical challenge that MCED tests—emerging blood-based screening tools capable of detecting up to 50 cancer types—have modest positive predictive...
- The National Cancer Institute awarded Emory University $639,077 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop rapid quantitative amide proton transfer-weighted (APTW) magnetic resonance imaging for brain tumor characterization at 3 Tesla field strength. The work addresses clinical challenges in chemical exchange saturation transfer (CEST) MRI by refining the quasi-steady-state (QUASS) algorithm to reconstruct equilibrium CEST signals...